Upcoming 2026 PSC Virtual Ophthalmology Symposium: Meet The Companies

Research evidence excerpt

Upcoming 2026 PSC Virtual Ophthalmology Symposium: Meet The Companies

on drug-device combination for keratoconus. MGTX 13.92

Therapeutics (KLRS, Amin), developing TH103, an anti-VEGF, that could OCUL 9.64 ◦Kalaris

provide extended durability and is currently in a Ph1b/2 trial. OKYO 1.57

Pharmaceuticals (KPRX), advancing two intravitreal programs: KIO-301 for ◦Kiora INDUSTRY RISKS advanced IRDs and DHODH inhibitor KIO-104 for retinal inflammation.

(MGTX, Bratzel), a late-stage genetic medicine company with Companies may fail to achieve development, ◦MeiraGTx

four pivotal-stage programs in ophthalmology, salivary gland disease, and regulatory, or commercial objectives.

neurodegeneration.

Therapeutics (private), a clinical-stage ocular gene therapy company ◦Nanoscope

developing MCO-010, an optogenetic therapy for retinitis pigmentosa with a rolling

BLA initiated in mid-25.

Therapeutix (OCUL, Amin), focused on Axpaxli, a sustained-release TKI ◦Ocular

intravitreal implant, for wet AMD and DR, and plans a NDA filing in 4Q'26.

(OCGN), advancing a modifier gene therapy platform and recently ◦Ocugen

completed enrollment in two pivotal trials for RP and Stargardt.

(OCS), refocusing on its precision medicine approach for dry eye disease ◦Oculis

and neuroprotective asset for optic neuropathies.

Pharma (OKYO, Amin), developing urcosimod, a first-in-class topical ◦OKYO

chemerin receptor agonist for neuropathic corneal pain.

Biosciences (private), developing OLN324, a next-gen VEGF/Ang2 ◦Ollin

bispecific with higher Ang2 potency and extended durability.

Therapeutics (private), developing xelafaslatide, a first-in-class intravitreal ◦ONL

Fas inhibitor, in dev't for GA/dry AMD, and chronic glaucoma.

Genetics (IRD, Amin), a gene therapy company for inherited retinal ◦Opus